Exhibit 1
Joint Filing Agreement
The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Shares of LAVA Therapeutics N.V. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.
April 8, 2021
Versant Venture Capital VI, L.P. | ||
By: | Versant Ventures VI GP, L.P. | |
Its: | General Partner | |
By: | Versant Ventures VI GP-GP, LLC | |
Its: | General Partner | |
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Ventures VI GP, L.P. | ||
By: | Versant Ventures VI GP-GP, LLC | |
Its: | General Partner | |
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Ventures VI GP-GP, LLC | ||
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Vantage I, L.P. | ||
By: | Versant Vantage I GP, L.P. | |
Its: | General Partner | |
By: | Versant Vantage I GP-GP, LLC | |
Its: | General Partner | |
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Vantage I GP, L.P. | ||
By: | Versant Vantage I GP-GP, LLC | |
Its: | General Partner | |
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Vantage I GP-GP, LLC | ||
By: | /s/ Robin L. Praeger, Managing Director |